Jun 08, 2022 / 09:00PM GMT
Malgorzata Maria Kaczor Andrew - William Blair & Company L.L.C., Research Division - Partner
Last meeting of the day, so thank you for everyone for sticking with us, and thanks for Jereme to being here as well. Good afternoon, everyone. For those of you that haven't met me yet, my name is Margaret Kaczor and I am the research analyst here at William Blair & Company who covers DexCom.
Before we begin, I do have to disclose the fact that I own -- personally own shares of DexCom. And beyond that, you can obtain a complete list of research disclosures or potential conflicts of interest at williamblair.com.
As I said, we're very pleased to have CFO, Jereme Sylvain, here with us. DexCom has been a name that probably has been at this conference well over a decade and a core holding, obviously, for a lot of people at the firm and beyond that. But the stocks actually pulled back quite a lot with the recent market downturn. So even as we look out over the next 12-, 18-, 24-plus months, the ROI for us in DexCom is still well in front of us.
And our thesis, while it still remains
Dexcom Inc at William Blair Growth Stock Conference Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers